FREEHOLD, NJ--(Marketwired - Aug 25, 2016) - MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the "Company" or "Medifirst") announced that it has engaged International Monetary ("IM") as its strategic advisory firm to provide advice on targeting candidates for strategic partnerships, rolling out its Time Machine Laser Series, and penetrating the medical device and laser industry.
A provider of innovative laser technology, Medifirst recently received FDA 510(k) clearance to bring to market its Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. Medifirst looks to IM to capitalize on this milestone achievement.
M.B. (Blaine) Riley, III, Managing Director and President of International Monetary, states, "From the moment our group saw Medifirst Solution's FDA-approved medical device technology, we immediately recognized the enormous potential for this young company and wanted to be part of what we expect will be one of the most talked about medical laser technology growth stories. We will work with Bruce on a number of strategic fronts to enable MFST to unlock the true value of the company's technology, which in turn will enhance shareholder value, and build the company into a leader of its field."
With almost 30 years of advisory experience servicing companies in the US capital markets, Mr. Riley is the Founder, President and Managing Partner of International Monetary (IM). Under Mr. Riley's leadership role, International Monetary has spearheaded and expanded business development efforts with private and public companies ranging from emerging growth to the middle market. Specializing in the healthcare industry and specifically in the biotech and medical device sectors while at Shearson Lehman Brothers (La Jolla, CA), Mr. Riley focused on the discovery of undervalued healthcare companies for affluent buy-side clients that included physician groups and medical practitioners while providing capital advisory services to public company CEOs and CFOs in the health care industry. Blaine has initiated, advised and managed over 100 company clients through the initial public offering (IPO) and reverse takeover (RTO) processes providing capital formation guidance and investor awareness (investor & public relations) services. Additionally, he implemented, developed, and organized IM's M&A advisory and consulting business, making it a top M&A advisory firm.
Stated CEO Bruce J. Schoengood, "IM is one of the premier consulting firms in the United States, catering specifically to small-cap public companies. With its team of professionals serving its corporate clients, IM has the experience and resources, including the medical device sector, to quickly facilitate business development and implementation and bring a substantial knowledgebase to the table for strategic decision making. We are pleased to be associated with this premier firm and to leverage their experience in this exciting industry. With the recent addition of Richard J. Berman to our Advisory Board, Medifirst is working diligently to bring on experienced professionals to help position Medifirst as a major player in the Lasers industry." The company anticipates additional announcements in the upcoming days and weeks.
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc., in response to its Premarket Notification 510(k) submission for "The Time Machine" Series Laser, received clearance from the U.S. Food and Drug Administration ("FDA") to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The Time Machine Series Lasers Model TTML-8102000 - 810/830nm is intended for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation and temporary relaxation of muscles by means of topical elevated tissue temperature from infrared spectral emissions. Due to the decrease of inflammation, patients have seen immediate aesthetic improvements as well, such as in scar and incision healing. The hand-held laser device, with pin-point accuracy, often gives patients immediate results with no redness, swelling or down-time. This unique laser device offers medical professionals an affordable and effective tool to enhance their treatment protocols for their patients and provide new revenue streams for their practice. The laser division will be operated out of Medifirst's wholly owned subsidiary, Medical Lasers Manufacturer. Visit www.medifirstsolutions.com for more information.
The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.